linjc16/ctgov huggingface dataset:
Correlation Between Carbon Dioxide Measured in End of Exhalation and Arterial Blood

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to study the correlation between carbon dioxide measured by capnography at the enf of exhalation and arterial blood in COPD patients with nasal cannula in critical care unit.

Official Title
-----------------
Correlation Between Carbon Dioxide Measured in End of Exhalation and Arterial Blood in Chronic Obstructive Pulmonary Disease (COPD) in Intensive Care Unit With Nasal Cannula

Conditions
-----------------
Correlation Between Exhaled Carbon Dioxide and in Arterial Blood

Intervention / Treatment
-----------------
* Other: To measure carbon dioxide by capnography and arterial blood
* Other: to measure carbon dioxide by capnography and arterial blood


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults COPD patients Exclusion Criteria: Under-aged Pregnant Major burns

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| respiratory<br> | Other: To measure carbon dioxide by capnography and arterial blood<br>* Three times per day will be measured exhaled carbon dioxide and obtained in arterial blood sample.<br>Other: to measure carbon dioxide by capnography and arterial blood<br>* three times per day we will obtained arterial blood samples and measurements of carbon dioxide by capnography<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Sun Protection Factor Assay (SPF Assay 105/2016)

Study Overview
=================
Brief Summary
-----------------
To evaluate the Sun Protection Factor efficacy on human skin.

Official Title
-----------------
Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay Minimal Persistent Pigment-Darkening Dose

Conditions
-----------------
Sunscreening Agents

Intervention / Treatment
-----------------
* Drug: BAY987517


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Fitzpatrick Skin Type l, ll and/or lll for UVB testing. Fitzpatrick Skin Type ll, lll and/or lV for UVA testing. Male and female. Aged between 18-70 years old. Good health as determined from the HRL SHF (Subject History Form). Signed and dated Informed Consent Form. Signed and dated HIPAA (Health Insurance Portability and Accountability Act) form. An unambiguous MED (Minimal Erythema Dose) or MPPD (Minimal Persistent Pigment Darkening Dose) Exclusion Criteria: Subjects on test at any other research laboratory or clinic. Known allergy or sensitivity to sunscreens, cosmetics and toiletries, topical drugs and/or ultraviolet light. Pre-existing dermatologic conditions which have been diagnoses by a medical professional (e.g. psoriasis, eczema, etc.)which would interfere with this study. Pre-existing other medical conditions (e.g. adult asthma, diabetes). Treatment with antihistamines or corticosteroids within one week prior to initiation of the test. Treatment with antibiotics within two weeks prior to initiation of the test. Chronic medication which could affect the results of the study. Known pregnant or nursing women.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: BAY987517<br>Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. | Drug: BAY987517<br>* Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z44-040)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Minimal Erythema Dose (MED) |  | Up to 15 minutes | 
| Minimal Persistent Pigment Darkening Dose (MPPD) |  | Up to 15 minutes |
Lidocaine In-situ Gel Before Intrauterine Device Insertion

Study Overview
=================
Brief Summary
-----------------
Intrauterine device can cause pain and discomfort in several ways: Use of the tenaculum to grasp the cervix and straighten the uterus for proper insertion; trans-cervical actions including measuring uterine depth, inserting the insertion tube, and removing the tube; and placement of the device in the uterus.

Official Title
-----------------
Effect of Self-administered Lidocaine In-situ Gel on Intrauterine Device Insertion Pain: A Randomized Controlled Trial

Conditions
-----------------
Pain Relief

Intervention / Treatment
-----------------
* Drug: lidocaine in-situ gel
* Drug: placebo in-situ gel


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women not taken analgesics or anxiolytics in the 24 hours prior insertion Women not taken misoprostol prior to insertion No contraindication to or history of allergic reaction to lidocaine Women who will accept to participate in the study Exclusion Criteria: Lidocaine allergy Any contraindication to device placement

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: lidocaine in-situ<br>Self-administered gel 10 min before intrauterine device insertion | Drug: lidocaine in-situ gel<br>* lidocaine in-situ gel<br>|
| Placebo Comparator: placebo<br>Self-administered gel 10 min before intrauterine device insertion | Drug: placebo in-situ gel<br>* placebo in-situ gel<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean pain score during intrauterine device insertion |  | 30 min |
Study of the Effect of Individualizing Daytrana Wear-times on Sleep in Children With ADHD

Study Overview
=================
Brief Summary
-----------------
Methylphenidate may improve sleep in children with ADHD. By leaving Daytrana (methylphenidate) patch for a longer time then 9 hours, many children report short sleep latencies and better quality of sleep.

Detailed Description
-----------------
Once the optimal dose of Daytrana that controlled the ADHD symptoms is established. The patch will be removed 1, 2, and 3 hours before bed time in a random fashion, at weekly intervals, and parents will keep a sleep diary. 25 patients will be enrolled in order to obtain statistical significance.

Official Title
-----------------
Open Label Study of the Effect of Individualizing Daytrana Wear-times on Sleep in Children 6-12 Years Old With Attention Deficit Hyperactivity Disorder (ADHD)

Conditions
-----------------
Attention Deficit Hyperactivity Disorder, INSOMNIA

Intervention / Treatment
-----------------
* Drug: Daytrana
* Drug: Daytrana
* Drug: Daytrana
* Drug: Daytrana


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ADHD without significant comorbidity Exclusion Criteria: Cardiac disorder Hypertension Thyroid disease Glaucoma History of sudden death, motor tics and/or Tourette's syndrome Hypersensitivity to methylphenidate

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Daytrana 9 hr wear<br> | Drug: Daytrana<br>* Daytrana patch 10-30 mg administered once daily for 9hr<br>* Other names: methylphenidate transdermal system;|
| Experimental: Daytrana 10 hr wear<br> | Drug: Daytrana<br>* Daytrana 10-30 mg worn once daily for 10 hr wear<br>* Other names: methylphenidate transdermal system;|
| Experimental: Daytrana 11 hr wear<br> | Drug: Daytrana<br>* Daytrana 10-30 mg worn once daily for 11 hr<br>* Other names: methylphenidate transdermal system;|
| Experimental: Daytrana 12 hr wear<br> | Drug: Daytrana<br>* Daytrana 10-30 mg worn once daily for 12 hrs<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sleep Latency | Measure by daily subject sleep diary | 9 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
sleep latency, adhd rating scales, daytrana, ADHD
Surface EMG Biofeedback for Children With Cerebral Palsy

Study Overview
=================
Brief Summary
-----------------
Movement disorders such as dystonia, hypertonia, and spasticity interfere with or prevent voluntary movement. Studies have suggested that using biofeedback to increase awareness of muscle activation can improve motor function in patients with motor deficits. The investigators hypothesize that the daily use of a surface electromyographic (SEMG) biofeedback device for one month will improve motor function in children and young adults with dystonia, hypertonia, and/or spasticity. The SEMG biofeedback device is worn over the muscle(s) the subject has difficulty in controlling and provides vibratory feedback about muscle activation. Groups of children and young adults (ages 3-21), with dystonia, hypertonia, and/or spasticity will be asked to wear a small (approx 1 square inch) sensory feedback device on their affected muscle(s) for 5 hours a day for one month. The device will vibrate and emit a blue light when the muscle is activated. At the start of the experiment, subjects will be tested on the Goal Attainment Scale (GAS), the Pediatric/Adolescent Outcomes Data Collections Instruments (PODCI), and the Barry Albright Dystonia Scale (BAD). For one month, subjects will practice goals without device. After a month, subject will be assessed again and be given device to practice goals for a month. After one month, the subjects will be tested on the outcome measures again and return device.

Official Title
-----------------
Clinical Trial of Surface EMG Biofeedback for Children With Cerebral Palsy and Associated Movement Disorders

Conditions
-----------------
Cerebral Palsy, Dystonia, Hypertonia, Spasticity, Movement Disorders

Intervention / Treatment
-----------------
* Device: Sanger EMG Biofeedback Device


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cerebral palsy, or associated movement disorders such as dystonia, spasticity, and/or hypertonia Able to wear device for given amount of time Exclusion Criteria: Unable to wear device for at least 5 hours day for a month.

Ages Eligible for Study
-----------------
Maximum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Surface EMG Biofeedback<br> | Device: Sanger EMG Biofeedback Device<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Goal Attainment Scale | The Goal Attainment Scale measures function in each of 5 areas that are individually chosen by the parents or adolescents at the initial visit. Parents and/or adolescents are encouraged to choose 2 basic movement goals and 3 goals related to function. | Two months |
Safety and Efficacy Study of Lithium in Bipolar Disorder

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether Lithium is safe and effective in the treatment of Bipolar I Disorder subjects with symptoms of acute mania.

Official Title
-----------------
Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter, Efficacy and Safety Study of Lithium in Bipolar I Disorder

Conditions
-----------------
Bipolar Disorder, Mania

Intervention / Treatment
-----------------
* Drug: Lithium Carbonate Capsule


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of Bipolar 1 Disorder; Hospitalized or in the process of being hospitalized for a manic or mixed episode Exclusion Criteria: History of rapid cycling; History of hypersensitivity or adverse reaction to lithium

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Lithium Carbonate Capsule|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change from baseline in YMRS score |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change from baseline in CGI-BP score |  |  | 
| change from baseline in MADRS score |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bipolar I Disorder, Bipolar Disorder, Lithium
Correlation Between Peripheral and Central Venous Blood Partial Pressure of Carbon Dioxide in Critical Ill Patients

Study Overview
=================
Brief Summary
-----------------
Observational study to analyze correlation between partial pressure of carbon dioxide from blood obtained from peripheral and central veins

Official Title
-----------------
Correlation Between Peripheral and Central Venous Blood Partial Pressure of Carbon Dioxide in Critical Ill Patients

Conditions
-----------------
Partial Pressure of Carbon Dioxide

Intervention / Treatment
-----------------
* Diagnostic Test: Peripheral venous blood sampling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients admitted to institutional ICU with central venous catheter in place Venous blood gas analysis ordered Exclusion Criteria: Central venous catheter malposition Difficult peripheral venous access

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Peripheral venous blood sampling|Blood collected from peripheral venous (extremities) and central venous (central catheter) for blood gas analyses|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difference between partial pressure of carbon dioxide | Difference between partial pressure of carbon dioxide taken from peripheral and central veins | 30 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
carbon dioxide, peripheral venous blood, central venous blood, venous blood gas, blood gas analysis, partial pressure of carbon dioxide
Influences of Phenylephrine, Dopamine and Ephedrine on Stroke Volume Variation and Pulse Pressure Variation

Study Overview
=================
Brief Summary
-----------------
Although induced hypertension decreased SVV and PPV,the influences of stroke volume variation and pulse pressure variation caused by phenylephrine,dopamine and ephedrine were unknown.

Detailed Description
-----------------
Pulse pressure variation (PPV) and stroke volume variation (SVV) during mechanical ventilation have been shown to be effective parameters to predict preload responsiveness. Although induced hypertension decreases PPV and SVV, the influences of phenylephrine, dopamine and ephedrine on PPV and SVV are unknown.

Official Title
-----------------
Influences of Phenylephrine, Dopamine and Ephedrine on Stroke Volume Variation and Pulse Pressure Variation

Conditions
-----------------
Circulation, Drug Dose, Calculated SAP

Intervention / Treatment
-----------------
* Other: Influences of phenylephrine, dopamine and ephedrine on stroke volume variation and pulse pressure variation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Their American Society of Anesthesiologists (ASA) physical status was 1 or 2 Body mass index (BMI) ranged from 18 to 26 None of the patients had known diabetes mellitus, hypertension, cardiovascular, pulmonary, endocrinological, neurological diseases, or diseases that influenced intravascular fluid volume or balance All patients had a preoperative fast for at least 8 h and routine atropine intramuscular injection Exclusion Criteria: Persistent arrhythmias Intraoperative application of vasoactive drugs except phenylephrine, dopamine and ephedrine

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: phenylephrine group, dopamine group, ephedrine group<br>phenylephrine group: use the phenylephrine to increase the SAP from low to high level. dopamine group: use the dopamine to increase the SAP from low to high level. ephedrine group:use the ephedrine to increase the SAP from low to high level. | Other: Influences of phenylephrine, dopamine and ephedrine on stroke volume variation and pulse pressure variation<br>* This research mainly study the effect of clinical commonly used vasoconstrictor drugs on blood pressure of pressure<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| invasive arterial blood pressure as a Measure of Safety | if instability of circulation, stop the clinical trial | DAY 1 |
Improving Sleep and Quality of Life in Adults With HIV Disease

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to see if yoga or music therapy can improve the sleep of adults with HIV.

Official Title
-----------------
Improving Sleep and Quality of Life in Adults With HIV Disease: A Pilot Study

Conditions
-----------------
Insomnia

Intervention / Treatment
-----------------
* Behavioral: Music Therapy
* Behavioral: Yoga


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: at least 18 years of age HIV seropositive current sleep disturbance able to speak, read, and write in English a phone number to maintain contact with research team willing to provide copy of most recent CD4 and viral load values willing to wear actigraph for 1 week per month for 3 months willing to participate in group intervention sessions 3 times per week for 8 weeks Exclusion Criteria: pregnancy psychiatric diagnosis, such as schizophrenia, dementia, bipolar disorder (depression not excluded) sleep disorder diagnosis, such as apnea or narcolepsy (insomnia not excluded) current yoga practice

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Yoga<br> | Behavioral: Yoga<br>* 1-hour yoga sessions administered in group format 3 times per week for 8 weeks<br>|
| Active Comparator: Music Therapy<br> | Behavioral: Music Therapy<br>* 1-hour music therapy sessions, administered in group format 3 times per week for 8 weeks.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| self-reported sleep disturbance |  | 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| actigraphic estimates of sleep quality and quantity |  | 8 weeks | 
| self-reported well-being |  | 8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HIV, sleep, insomnia, yoga, music